Frontier Pharma: Cancer Immunotherapies - First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets

Tuesday, October 10, 2017 Corporate News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Oct. 9, 2017 /PRNewswire/ -- Frontier Pharma: Cancer Immunotherapies - First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets

Read the full report: https://www.reportlinker.com/p05136762SummaryCancer is a group of diseases that are defined by abnormal cell growth, local tissue invasion and eventual migration to other parts of the body. The diseases are driven
by the accumulation of genetic mutations, which provide selective advantages to cells allowing them to evolve and propagate virtually all sites and tissues in the human body.Cancer currently stands as the second leading cause of death in economically developed countries globally, surpassed only by heart disease (World Health Organization, 2017). Across the eight major developed markets (the US, the UK, France, Germany, Italy, Spain, Japan and Canada) there were a total of 3.6 Million incident cases of cancer, and 11.2 Million five-year prevalent cases across the top 20 most common sites in 2012. Its prevalence across the globe presents a huge health burden, with over 14 Million new cases being diagnosed in 2012, with a five-year prevalence of 32.6 Million.Approximately 26 Million new cancer cases and 17 Million cancer deaths per year are projected by 2030 (Ferlay et al., 2015). This increase in cancer incidence and mortality is forecast to be driven by population growth and aging across developed and developing countries, with the global population forecast to reach 8.3 billion by 2030.The two most common cancers by five-year prevalence are prostate and breast cancers, with 696 and 686 prevalent cases per 500,000 respectively. These have 559,000 and 560,000 incident cases each year, respectively. The other most common cancers comprise a variety of sites across almost all organ systems, with only the CNS and skeletal system not being represented among the top 20 cancers by site.The report "Frontier Pharma: Cancer Immunotherapies - First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets" is a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.Specifically, this report -- Visualize the composition of the cancer immunotherapies market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed.- Analyze the cancer immunotherapies pipeline and stratify by stage of development, molecule type and molecular target.- Assess the therapeutic potential of first-in-class targets. Using a proprietary molecular target matrix tailored directly towards cancer immunotherapies, first-in-class products have been assessed and ranked according to clinical potential.- Helps to identify commercial opportunities in the cancer immunotherapies deals landscape by analyzing trends in licensing and co-development deals, and producing a list of first-in-class therapies with no prior involvement in licensing or co-development deals.Scope- The 3,100 products in active development, of which 989 are first-in-class and therefore act on completely novel targets, far exceed the scope of the current market. How will pipeline innovation affect the future cancer immunotherapies market?- There are 322 distinct first-in-class molecular targets currently being studied. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?- Multiple types of cancer immunotherapies exist. Which of these are the most promising, and how does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?- A significant number of first-in-class products have been identified with some prior involvement in deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?Reasons to buy- Understand the current clinical and commercial landscape. The report includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.- Visualize the composition of the cancer immunotherapies market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.- Analyze the cancer immunotherapies pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking immunotherapeutic approaches to treating cancer indications with current poor prognoses, including melanoma and lung cancer.- Assess the therapeutic potential of first-in-class targets. Using a proprietary molecular target matrix tailored directly towards cancer immunotherapies, first-in-class products have been assessed and ranked according to clinical potential.- Identify commercial opportunities in the cancer immunotherapies deals landscape by analyzing trends in licensing and co-development deals, and producing a list of first-in-class therapies with no prior involvement in licensing or co-development deals.Read the full report: https://www.reportlinker.com/p05136762 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. https://www.reportlinker.com __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/frontier-pharma-cancer-immunotherapies---first-in-class-pipeline-dominated-by-immunomodulators-and-pd-1-like-targets-300533340.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store